TVGN · NASDAQ
Average $102.00 (+1395.6% upside)
The latest rating actions, newest first
| Firm | Date | Action | Rating |
|---|---|---|---|
| D. Boral Capital | Mar 4, 2026 | Downgrade | Buy → Hold |
| D. Boral Capital | Mar 3, 2026 | Maintains | Buy |
| D. Boral Capital | Nov 20, 2025 | Maintains | Buy |
Updated Aug 18, 2026
Tevogen is facing multiple challenges that are impacting its stock price, including dilution risk and a recently announced 50:1 reverse stock split. These decisions have led to a decrease in our price target and a downgrade from Buy to Hold in our rating. Despite these issues, we still have a positive outlook on the company due to its focus on biotechnology, AI, and technology in the healthcare industry, which holds strong potential for growth and success in the future.
Tevogen is significantly diluting its existing shareholders with the reverse stock split, leading to reduced liquidity and a shrinking shareholder base. Additionally, the company faces multiple risks in its various business segments, including clinical/regulatory, financial, commercial, legal and intellectual property, and market share risks, which may further impact its financial performance and the sentiment around the company. The potential acquisition of a contract research organization may bring strategic and financial benefits, but there is no assurance of completion, and the company is also investing in other areas, such as Tevogen.AI, suggesting a lack of focus and potential for further dilution and financial risks.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
